{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:15:43Z","timestamp":1787066143345,"version":"build-2736575974"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","award":["ZYJC21043"],"award-info":[{"award-number":["ZYJC21043"]}],"id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["2021YFH0142"],"award-info":[{"award-number":["2021YFH0142"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31971390"],"award-info":[{"award-number":["31971390"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.heliyon.2023.e23929","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T17:01:38Z","timestamp":1705510898000},"page":"e23929","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["A bibliometric and knowledge-map analysis of bispecific antibodies in cancer immunotherapy from 2000 to 2023"],"prefix":"10.1016","volume":"10","author":[{"given":"Jing","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.heliyon.2023.e23929_bib1","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/ni.2392","article-title":"Immunology beats cancer: a blueprint for successful translation","volume":"13","author":"Pardoll","year":"2012","journal-title":"Nat. Immunol."},{"issue":"3441","key":"10.1016\/j.heliyon.2023.e23929_bib2","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1126\/science.132.3441.1770","article-title":"Properties of the major component of a peptic digest of rabbit antibody","volume":"132","author":"Nisonoff","year":"1960","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e23929_bib3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4161\/mabs.4.2.19000","article-title":"Dual targeting strategies with bispecific antibodies","volume":"4","author":"Kontermann","year":"2012","journal-title":"mAbs"},{"issue":"8","key":"10.1016\/j.heliyon.2023.e23929_bib4","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e23929_bib5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nbt0297-159","article-title":"Design and production of novel tetravalent bispecific antibodies","volume":"15","author":"Coloma","year":"1997","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e23929_bib6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/13543776.2018.1428307","article-title":"Therapeutic bispecific antibody formats: a patent applications review (1994-2017)","volume":"28","author":"Godar","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e23929_bib7","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"mAbs"},{"issue":"3","key":"10.1016\/j.heliyon.2023.e23929_bib8","first-page":"507","article-title":"FDA approves Genentech\u2019s bispecific antibody for lymphoma","volume":"29","author":"Carvalho","year":"2023","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e23929_bib9","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nbt0315-219","article-title":"Amgen\u2019s bispecific antibody puffs across finish line","volume":"33","author":"Sheridan","year":"2015","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e23929_bib10","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nbt.2797","article-title":"Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface","volume":"32","author":"Lewis","year":"2014","journal-title":"Nat. Biotechnol."},{"issue":"41","key":"10.1016\/j.heliyon.2023.e23929_bib11","doi-asserted-by":"crossref","first-page":"12806","DOI":"10.1073\/pnas.1509667112","article-title":"Noninvasive brain cancer imaging with a bispecific antibody fragment, generated via click chemistry","volume":"112","author":"Luo","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.heliyon.2023.e23929_bib12","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1016\/j.ymthe.2022.05.003","article-title":"LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation","volume":"30","author":"Sung","year":"2022","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23929_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13045-021-01045-x","article-title":"The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-\u03b2 and PD-L1","volume":"14","author":"Yi","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.heliyon.2023.e23929_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2019.102625","article-title":"DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing","volume":"52","author":"Engelberts","year":"2020","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.heliyon.2023.e23929_bib15","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1158\/2159-8290.CD-NB2022-0030","article-title":"MEDI5752 Suppresses two immune checkpoints","volume":"12","year":"2022","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e23929_bib16","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1182\/blood-2016-08-735365","article-title":"An anti-CD3\/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia","volume":"129","author":"Leong","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2023.e23929_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120760","article-title":"Development of an antibody-like T-cell engager based on VH-VL heterodimer formation and its application in cancer therapy","volume":"271","author":"Jang","year":"2021","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e23929_bib18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00063030-200923020-00003","article-title":"Strategies to extend plasma half-lives of recombinant antibodies","volume":"23","author":"Kontermann","year":"2009","journal-title":"BioDrugs"},{"issue":"3","key":"10.1016\/j.heliyon.2023.e23929_bib19","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.heliyon.2023.e23929_bib20","doi-asserted-by":"crossref","first-page":"Of13","DOI":"10.1158\/2159-8290.CD-RW2022-082","article-title":"A patient-derived organoid screen identified the bispecific antibody MCLA-158","volume":"12","year":"2022","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.heliyon.2023.e23929_bib21","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/ijc.25423","article-title":"The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II\/III trial","volume":"127","author":"Heiss","year":"2010","journal-title":"Int. J. Cancer"},{"issue":"18","key":"10.1016\/j.heliyon.2023.e23929_bib22","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-15-0612","article-title":"FDA approval: blinatumomab","volume":"21","author":"Przepiorka","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"17","key":"10.1016\/j.heliyon.2023.e23929_bib23","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Fo\u00e0","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.heliyon.2023.e23929_bib24","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","article-title":"Blinatumomab added to chemotherapy in infant lymphoblastic leukemia","volume":"388","author":"van der Sluis","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.heliyon.2023.e23929_bib25","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.heliyon.2023.e23929_bib26","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-aALL","volume":"40","author":"Myers","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.heliyon.2023.e23929_bib27","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1200\/JCO.21.01766","article-title":"SWOG 1318: a phase II trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia","volume":"40","author":"Advani","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2023.e23929_bib28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.copbio.2019.11.020","article-title":"Bispecific antibodies in cancer immunotherapy","volume":"65","author":"Rader","year":"2020","journal-title":"Curr. Opin. Biotechnol."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e23929_bib29","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41423-020-0417-8","article-title":"Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics","volume":"17","author":"Li","year":"2020","journal-title":"Cell. Mol. Immunol."},{"issue":"33","key":"10.1016\/j.heliyon.2023.e23929_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abi8193","article-title":"A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand","volume":"7","author":"Lee","year":"2021","journal-title":"Sci. Adv."},{"issue":"10","key":"10.1016\/j.heliyon.2023.e23929_bib31","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1158\/1078-0432.CCR-20-3716","article-title":"Safety and immunogenicity of LY3415244, a bispecific antibody against TIM-3 and PD-L1, in patients with advanced solid tumors","volume":"27","author":"Hellmann","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e23929_bib32","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ymthe.2023.02.010","article-title":"An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers","volume":"31","author":"Zekri","year":"2023","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23929_bib33","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13045-019-0812-8","article-title":"Targeting cancers through TCR-peptide\/MHC interactions","volume":"12","author":"He","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23929_bib34","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s13045-020-01012-y","article-title":"GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma","volume":"13","author":"Park","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23929_bib35","doi-asserted-by":"crossref","first-page":"148","DOI":"10.7150\/thno.79367","article-title":"Blockade of dual immune checkpoint inhibitory signals with a CD47\/PD-L1 bispecific antibody for cancer treatment","volume":"13","author":"Wang","year":"2023","journal-title":"Theranostics"},{"issue":"584","key":"10.1016\/j.heliyon.2023.e23929_bib36","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd3595","article-title":"TCR \u03b2 chain-directed bispecific antibodies for the treatment of T cell cancers","volume":"13","author":"Paul","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23929_bib37","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/leu.2008.271","article-title":"A bispecific single-chain antibody that mediates target cell-restricted, supra-agonistic CD28 stimulation and killing of lymphoma cells","volume":"23","author":"Otz","year":"2009","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e23929_bib38","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s11192-017-2300-7","article-title":"Citation-based clustering of publications using CitNetExplorer and VOSviewer","volume":"111","author":"van Eck","year":"2017","journal-title":"Scientometrics"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23929_bib39","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2017-06-741058","article-title":"Redirecting T cells to hematological malignancies with bispecific antibodies","volume":"131","author":"Velasquez","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.heliyon.2023.e23929_bib40","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1056\/NEJMe1707802","article-title":"Bispecific antibody therapy in hemophilia","volume":"377","author":"Lillicrap","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.heliyon.2023.e23929_bib41","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/nrd.2017.237","article-title":"Cancer: bispecific antibody directs T cells to solid tumours","volume":"16","author":"Cully","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23929_bib42","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13045-021-01126-x","article-title":"Anticancer bispecific antibody R&D advances: a study focusing on research trend worldwide and in China","volume":"14","author":"Zhang","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23929_bib43","first-page":"43","article-title":"New developments in monoclonal antibodies for cancer detection and therapy","volume":"44","author":"Goldenberg","year":"1994","journal-title":"CA A Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e23929_bib44","first-page":"226","article-title":"Targeted therapy of cancer: new prospects for antibodies and immunoconjugates","volume":"56","author":"Sharkey","year":"2006","journal-title":"CA A Cancer J. Clin."},{"issue":"23 Suppl","key":"10.1016\/j.heliyon.2023.e23929_bib45","first-page":"5864s","article-title":"Development and characterization of anti-renal cell carcinoma x antichelate bispecific monoclonal antibodies for two-phase targeting of renal cell carcinoma","volume":"55","author":"Kranenborg","year":"1995","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e23929_bib46","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/protein\/9.7.617","article-title":"'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization","volume":"9","author":"Ridgway","year":"1996","journal-title":"Protein Eng."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e23929_bib47","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood.V95.6.2098","article-title":"A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes","volume":"95","author":"L\u00f6ffler","year":"2000","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.heliyon.2023.e23929_bib48","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/ijc.10557","article-title":"Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody","volume":"100","author":"Dreier","year":"2002","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e23929_bib49","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/sj.leu.2402890","article-title":"Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19\/anti-CD3 single-chain antibody construct","volume":"17","author":"L\u00f6ffler","year":"2003","journal-title":"Leukemia"},{"issue":"5891","key":"10.1016\/j.heliyon.2023.e23929_bib50","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"issue":"18","key":"10.1016\/j.heliyon.2023.e23929_bib51","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23929_bib52","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.heliyon.2023.e23929_bib53","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e23929_bib54","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.molimm.2005.03.007","article-title":"Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells","volume":"43","author":"Offner","year":"2006","journal-title":"Mol. Immunol."},{"issue":"12","key":"10.1016\/j.heliyon.2023.e23929_bib55","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","article-title":"Bispecific T-cell engaging antibodies for cancer therapy","volume":"69","author":"Baeuerle","year":"2009","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e23929_bib56","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/d41573-022-00040-2","article-title":"Bispecific antibodies in oncology","volume":"21","author":"Esfandiari","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e23929_bib57","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1200\/JCO.20.01564","article-title":"Immunotherapy of acute lymphoblastic leukemia and lymphoma with T cell-redirected bispecific antibodies","volume":"39","author":"Lussana","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.heliyon.2023.e23929_bib58","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1200\/JCO.21.01987","article-title":"In multiple myeloma, high-risk secondary genetic events observed at relapse are present from diagnosis in tiny, undetectable subclonal populations","volume":"41","author":"Lannes","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.heliyon.2023.e23929_bib59","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1200\/JCO.22.02665","article-title":"Daratumumab, bortezomib, and dexamethasone for previously treated multiple myeloma","volume":"41","author":"Huang","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"10396","key":"10.1016\/j.heliyon.2023.e23929_bib60","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"van de Donk","year":"2023","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.heliyon.2023.e23929_bib61","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s40265-022-01793-1","article-title":"Teclistamab: first approval","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.heliyon.2023.e23929_bib62","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1200\/JCO.20.01370","article-title":"Health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma: findings from the phase III MAIA trial","volume":"39","author":"Perrot","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"10301","key":"10.1016\/j.heliyon.2023.e23929_bib63","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen \u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.heliyon.2023.e23929_bib64","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.heliyon.2023.e23929_bib65","first-page":"626","article-title":"BCMA-targeted bispecific gets first green light, in the EU","volume":"21","author":"Mullard","year":"2022","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023111376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023111376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:22:47Z","timestamp":1783930967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844023111376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2405844023111376"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e23929","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A bibliometric and knowledge-map analysis of bispecific antibodies in cancer immunotherapy from 2000 to 2023","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e23929","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e23929"}}